Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations

To learn about the safety and tolerability of study drug combinations in patients with relapsed/refractory, IDH1-mutated myeloid malignancies with a co-signaling mutation.

NCT Number	NCT07032727
Lead Sponsor	M.D. Anderson Cancer Center Collaborators: Rigel Pharmaceuticals
Conditions	Targeted Therapy, IDH1-Mutated Malignancies, Mutations
Enrollment	68 participants
Start Date	2025-09-12
Primary Completion	2027-06-01 (estimated)
Study Completion	2029-06-01 (estimated)
Updated on ClinicalTrials.gov	2026-04-15